June 4, 2021 by Chain Drug Review
hase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab, Novartis
Pharmacy, Supplier News
EAST HANOVER, N.J.— Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001). The study evaluated tislelizumab in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who
February 17, 2021 by Chain Drug Review
Entresto (sacubitril/valsartan), Novartis
Pharmacy, Supplier News
EAST HANOVER, N.J.— Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved the following expanded indication for Entresto (sacubitril/valsartan): to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF)
November 18, 2019 by Chain Drug Review
Biofourmis, commercial project for managing patients with heart failure, Kuldeep Singh Rajput, Novartis
Pharmacy, Supplier News
BOSTON – Biofourmis announced Monday it has been selected by Novartis, a global healthcare company, to collaborate on a commercial project for managing patients with heart failure (HF) beginning in Southeast Asia, with potential plans to expand globally. The goal of the program is to improve clinical outcomes by using Biofourmis’ lead product BiovitalsHF, which
June 6, 2019 by Chain Drug Review
Dr. E. Anne Peterson, Healthcare Distribution Alliance (HDA), Novartis, Sandoz
Leading Headlines, Pharmacy, Uncategorized
STAMFORD, Conn. – Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Novartis and its Sandoz division, in recognition of their outstanding commitment to increasing access to health care around the world. Americares senior vice president of global programs Dr. E. Anne Peterson presented the award
March 18, 2019 by Chain Drug Review
Alcon, arry Cheskin, Michael Onuscheck, Novartis, president and chief executive officer and cofounder of PowerVisio
Leading Headlines, Supplier News
FORT WORTH — Alcon, the global leader in eye care and a division of Novartis, announced Monday that it has acquired PowerVision, Inc., a privately-held, US-based medical device development company focused on creating fluid-based intraocular lens implants. The acquisition furthers Alcon’s commitment to bring this innovative, accommodating lens to cataract patients throughout the world. Commercial availability
March 15, 2019 by Chain Drug Review
Francesco Balestrieri, Novartis, Richard Francis, Sandoz, Vas Narasimhan
Leading Headlines, Supplier News
BASEL – Novartis announced this week that Richard Francis will be stepping down as chief executive officer of Sandoz, a Novartis division, and as a member of the executive committee of Novartis on March 31. Francesco Balestrieri, currently region head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.
March 5, 2019 by Chain Drug Review
CLARITY study demonstrating the superiority of Cosentyx (secukinumab), Novartis, Stelara (ustekinumab)
Pharmacy, Supplier News
BASEL — Novartis announced Tuesday additional results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx (secukinumab) compared to Stelara (ustekinumab) in delivering specific quality of life (QoL) aspects in adults with moderate-to-severe plaque psoriasis at 16 weeks. New CLARITY data show over two-thirds of Cosentyx treated patients with moderate to severe psoriasis reported no impact of
December 19, 2018 by Chain Drug Review
biosimilars, Novartis, Sandoz, type 1 and type 2 diabetes
Supplier News
HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that it has entered into an agreement to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes. These medicines are currently in early and clinical stages of development for the European Union (E.U.),
November 20, 2018 by Chain Drug Review
Dr. Corey McCann, Novartis, Pear Therapeutics, reSet, reSET Connect Patient Service Center, Richard Francis, Sandoz, Substance Use Disorder (SUD)
Supplier News
HOLZKIRCHEN— Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch of reSET for patients with Substance Use Disorder (SUD). reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available. Study results from a multicenter, randomized clinical trial showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence
October 31, 2018 by Chain Drug Review
biosimilars, Hyrimoz (adalimumab-adaz), Novartis, Sandoz, Stefan Hendriks
Supplier News
HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn’s
September 6, 2018 by Chain Drug Review
Aurobindo Pharma USA Inc, Novartis, Richard Francis, Sandoz U.S. portfolio
Business, Leading Headlines, Pharmacy, Supplier News
BASEL— Novartis today announced it has agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs. This transaction supports the Sandoz strategy of focusing on complex
June 29, 2018 by Chain Drug Review
Alcon, Dr. Vas Narasimhan, Joerg Reinhardt, Novartis
Business, Leading Headlines, Supplier News
BASEL — Novartis today announced its intention to spinoff Alcon, its eye care division, into a separately-traded standalone company. The planned spinoff would enable Novartis and Alcon to focus fully on their respective growth strategies. Completion of the transaction is subject to general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder
May 19, 2018 by Chain Drug Review
Aimovig, Amgen, migraine, migraine prevention, Novartis, Novartis Pharmaceuticals, Paul Hudson
Pharmacy, Supplier News
Basel, SWITZERLAND – Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to
May 12, 2018 by Chain Drug Review
Dr. Brenda Banwell, Fabrice Chouraqui, multiple sclerosis, Novartis
Pharmacy, Supplier News
EAST HANOVER, N.J. — Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to less than 18 years of age with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for these patients. This approval expands the age range